Revolution Medicines, Inc. (RVMD) Revenue by Segment & Business Profile
RAS(ON) inhibitors (e.g., RMC-6236, RMC-6291) for RAS-addicted cancers was 80.0% of Revolution Medicines, Inc.'s revenue across the 2 lines it reports, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 40.1B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
What the company does
Revolution Medicines, Inc. is a biotechnology company in the healthcare sector. In its SEC filings it reports 2 business lines: RAS(ON) inhibitors (e.g., RMC-6236, RMC-6291) for RAS-addicted cancers (80%), RAS companion inhibitors for combination therapy in oncology (20%). Trailing twelve-month revenue: $0 as of 2026-06-30.
Roles we read
from the filings, not the sector label- Clinical-stage developer
Revolution Medicines, Inc. — questions
- What does Revolution Medicines, Inc. do?
- Revolution Medicines, Inc. is a biotechnology company in the healthcare sector. In its SEC filings it reports 2 business lines: RAS(ON) inhibitors (e.g., RMC-6236, RMC-6291) for RAS-addicted cancers (80%), RAS companion inhibitors for combination therapy in oncology (20%). Trailing twelve-month revenue: $0 as of 2026-06-30.
- How does Revolution Medicines, Inc. make money?
- By the lines it reports in its SEC filings: RAS(ON) inhibitors (e.g., RMC-6236, RMC-6291) for RAS-addicted cancers 80.0%, RAS companion inhibitors for combination therapy in oncology 20.0% of revenue.
Every figure on this page comes from Revolution Medicines, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.